Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Catherine S. Grasso(University of California, Los Angeles), Antoni Ribas(University of California, Los Angeles), Gabriel Abril-Rodríguez(University of California, Los Angeles), Cristina Puig-Saus(APLA Health), John B.A.G. Haanen(Leiden University Medical Center), Douglas B. Johnson(Vanderbilt University Medical Center), Walter J. Urba(Providence Portland Medical Center), Salvador Martín‐Algarra(Clinica Universidad de Navarra), Agustin Vega-Crespo(University of California, Los Angeles), Adi Diab(Cleveland Clinic), Shailender Bhatia(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Michael J. Quist(University of California, Los Angeles), Bartosz Chmielowski(UCLA Health), Ameya S. Champhekar(University of California, Los Angeles), Katie M. Campbell(University of California, Los Angeles), Suzanne L. Topalian(Bloomberg (United States)), Jedd D. Wolchok(Cornell University), Valsamo Anagnostou(Johns Hopkins University), Egmidio Medina(University of California, Los Angeles), Davis Y. Torrejon(APLA Health), Jason J. Luke(University of Chicago), Drew M. Pardoll(Bloomberg (United States)), Daniel Sanghoon Shin(Michael E. DeBakey VA Medical Center), Phuong Tran(University of California, Los Angeles), Christophe Martignier(University of Lausanne), Daniel E. Speiser(University of Lausanne), F. Stephen Hodi(Harvard University), William H. Sharfman(Johns Hopkins University), Anusha Kalbasi(Stanford Medicine), Craig L. Slingluff(University of Virginia Health System), Megan Wind‐Rotolo(Bristol-Myers Squibb (United States)), Mykola Onyshchenko(University of California, Los Angeles), Yeon Joo Kim(University of Ulsan), Victor E. Velculescu(Johns Hopkins University), Jennifer Tsoi(University of California, Los Angeles), Petra Ross‐Macdonald(Bristol-Myers Squibb (United States))
Cited by 379
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Cancer Genome Landscapes
|Science|2013|8k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k